Absco Therapeutics, Inc. (AbscoTx) is an innovative immune engineering company that has emerged from a collaborative effort involving clinicians from Massachusetts General Hospital and Brigham and Women’s Hospital, alongside engineers from MIT. This unique partnership combines clinical expertise with advanced engineering principles to develop novel therapeutic solutions aimed at enhancing immune responses. The company focuses on translating cutting-edge research into practical applications that can significantly impact patient care and treatment outcomes.

The technologies developed by AbscoTx are centered around immune modulation and engineering, leveraging insights from both clinical practice and engineering disciplines. By integrating these fields, AbscoTx aims to create therapies that can effectively target and manipulate the immune system, potentially leading to breakthroughs in treating various diseases. The company's commitment to translational medicine ensures that their innovations are not only scientifically robust but also aligned with the needs of patients and healthcare providers.

United States

Absco Therapeutics, Inc. (AbscoTx) is a stealth phase immune engineering company born out of collaborative work between clinicians at MGH and BWH, engineers at MIT, and an experienced team of biotech entrepreneurs and translational medicine experts.

Absco Therapeutics

Company Details